A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1--letter.

We would like to comment on a recently published research article in your journal, entitled “A Synthetic Lethality-Based Strategy to Treat Cancers Harboring a Genetic Deficiency in the Chromatin Remodeling Factor BRG1,” by Oike and colleagues ([1][1]). This article attempts to demonstrate that